Tesamorelin vs retatrutide for belly fat
Reviewed 20 sourcesPublished by PepVault
Tesamorelin cut deep belly fat 14-18% with no weight change; retatrutide took up to 48% off at its top dose, with 26% weight loss. Who each was tested in.

- Last reviewed
- Sources
- 20
- Questions
- 8
- Compounds
- 2
The short answer
They shrink belly fat in opposite ways. Tesamorelin, FDA-approved for abdominal fat in HIV lipodystrophy, cut visceral fat (the deep fat around the organs) by 14-18% in 26 weeks while weight stayed flat. Retatrutide, still unapproved as of November 2026, took 16-48% of visceral fat off in a 48-week MRI study, the top figure at the top dose alongside a 26% weight loss.
Evidence: Human trials for both, in different people: two phase 3 trials of tesamorelin in 806 adults with HIV plus one 60-person obesity trial; for retatrutide, phase 2 and phase 3 obesity trials with one 98-person MRI substudy. No study has compared or combined the two.

How do tesamorelin and retatrutide reduce belly fat?
Tesamorelin works on one fat depot. It is a lab-made copy of growth hormone-releasing hormone (GHRH, the brain's signal to the pituitary), so the pituitary releases more of its own growth hormone and the liver makes more IGF-1, a growth factor that carries part of its effect1. Growth hormone breaks down stored fat, and in its trials the deep fat inside the abdomen answered while the fat just under the skin of the belly did not change significantly, and neither did body weight1519.
Retatrutide works on the whole body. It is a triple agonist: one molecule that switches on the GLP-1, GIP and glucagon receptors, hormone signals behind appetite, insulin release and blood sugar6. People eat less and lose weight, and visceral fat comes off with everything else, faster than the scale moves8. The sibling guide on tesamorelin and visceral fat covers tesamorelin's own trials in detail; this page sets the two side by side.

Tesamorelin vs retatrutide: how do they compare?
Every number below is the label's or a trial's, as of November 20, 2026. The doses are the ones the label and the trials used, not a recommendation.
| Measure | Tesamorelin | Retatrutide |
|---|---|---|
| What it is | GHRH analog: raises your own growth hormone and IGF-11 | GLP-1, GIP and glucagon receptor agonist6 |
| Approval, November 2026 | FDA-approved since November 10, 2010 (Egrifta), only to reduce excess abdominal fat in adults with HIV and lipodystrophy13 | Not approved anywhere (Lilly, October 28, 2026)13; Lilly plans to file for FDA approval in the first quarter of 202720 |
| Studied in | Adults with HIV and abdominal fat; average weight 88-90 kg, waist 104-105 cm1 | Adults with obesity or overweight; MRI substudy average BMI 38.4, waist 118 cm8 |
| How belly fat was measured | CT: visceral fat area on one slice, in cm²1 | MRI: visceral fat volume, in litres8 |
| Visceral fat change | −18% vs +2% and −14% vs −2% on placebo at 26 weeks1 | −16% to −48% across doses vs +2.5% on placebo at 48 weeks8 |
| Weight change | −0.4 kg and +0.5 kg at 26 weeks, no different from placebo1 | −24.2% at 48 weeks (12 mg, phase 2)6; −25.0% vs −3.9% at 80 weeks (12 mg, phase 3, everyone randomised)10, −28.3% in people who stayed on treatment11 |
| Waist change | −3 cm and −2 cm vs −1 cm on placebo1 | −19.6 cm vs −2.6 cm at 48 weeks (12 mg, phase 2)7; −24.1 cm vs −3.6 cm at 80 weeks (12 mg, phase 3, in people who stayed on treatment)11 |
| Dosing in the label or trials | One injection a day1 | One injection a week, stepped up every 4 weeks6 |
| Half-life | 8-11 minutes12 | About 6 days14 |
| Most common side effects | Injection-site reactions 17% vs 6%, joint pain 13% vs 11%1 | Diarrhoea 34% vs 13%, nausea 28% vs 8% at 12 mg (TRIUMPH-2, obesity with type 2 diabetes)12 |
The two visceral-fat rows come from different scans in different people, so the percentages are not a head-to-head result. The retatrutide figure comes from 98 adults with fatty liver, about 20 per dose group at the start and only 8 or 9 per group with a scan at week 48, and its authors call the substudy hypothesis-generating8. Lilly reports trial results two ways: for everyone randomised, and as if everyone had stayed on treatment; the table labels which is which.
Which removes more visceral fat, tesamorelin or retatrutide?
In percentage terms, retatrutide, by a wide margin. In the MRI substudy of the phase 2 obesity trial, visceral fat fell 13.8-31.5% by week 24 and 16.1-48.3% by week 48, depending on the dose, while it rose 0.7% and 2.5% on placebo8. Between weeks 24 and 48 visceral fat kept falling as weight did, while liver fat held where it had reached8. Tesamorelin's two phase 3 trials, by the label's analysis, moved visceral fat 18% and 14% at 26 weeks1; the first trial's paper reported −15.2% against +5.0% on placebo4.
Per kilo lost, tesamorelin wins. It took visceral fat down with no change in weight at all, and lean body mass rose about 1.2-1.3 kg1. On retatrutide, visceral fat fell about twice as fast as body weight in percentage terms (−48% against −26% at the top of each range), and the fat under the skin of the belly fell almost as much, 13-44%8. That is the pattern of large weight loss: fat leaves from everywhere, the deep depot a little faster.
So the two answer different problems. Retatrutide shrinks a large body, belly included. Tesamorelin moves fat out of one place in a body whose size stays the same.
Why does the scale move on one and not the other?
Because only one of them changes how much you eat. Retatrutide's GLP-1 and GIP arms quiet appetite, so people take in less energy and lose weight from fat and, to a smaller degree, lean tissue. In a body-composition substudy of 189 adults with type 2 diabetes, scanned by DXA (a low-dose X-ray that splits fat from lean mass), total fat mass fell 23.2% at 36 weeks on 12 mg against 4.5% on placebo, and the share of weight lost as lean mass was similar to other obesity treatments9.
Tesamorelin leaves appetite alone. Its label states that it is "not indicated for weight loss management as it has a weight neutral effect"1. The fat it removes from the middle is roughly matched by the lean tissue that growth hormone adds, so the scale stays put while the waist comes in a few centimetres1.
PepVault charts every weigh-in and your waist check-ins as trends, so a flat scale with a shrinking waist shows up as what it is. Track your weight in PepVault
Lean with stubborn belly fat, or living with obesity: which question is yours?
Most people searching this fall into one of two groups, and the trials only speak to one at a time.
- Living with obesity. Retatrutide's trials enrolled adults with a BMI of 30 or more, or 27 or more with a weight-related condition6. In the phase 3 TRIUMPH-1 trial of 2,339 adults without diabetes, the 12 mg group lost 25.0% of body weight at 80 weeks against 3.9% on placebo10. Tesamorelin has one controlled trial here: 60 adults with abdominal obesity who also had low growth hormone output, where visceral fat fell 16 cm² while it rose 19 cm² on placebo over 12 months5.
- A normal or near-normal weight with a thick middle. Neither drug has been tested in this group outside HIV. Tesamorelin's phase 3 trials come closest: people with HIV who carried excess abdominal fat at an average weight of about 90 kg14. Retatrutide's obesity trials enrolled no one below a BMI of 276, and its diabetes trials no one below 259.
The link between the two is growth hormone itself. Obesity is associated with reduced growth hormone secretion, which is why the non-HIV tesamorelin trial selected people whose output was low5. Whether tesamorelin does the same for a lean person with normal growth hormone output has not been studied. A 2026 report of two people with HIV describes exactly this split: a person with a BMI of 27 and a large waist whose waist came in on tesamorelin, and a woman with obesity whose belly fat persisted on a GLP-1 drug she could only get on and off, to which tesamorelin was then added15. It is two cases, not a trial, and two of its four authors work for tesamorelin's maker while the other two have taken its speaker fees15.
Has anyone studied tesamorelin and retatrutide together?
No. On November 20, 2026, ClinicalTrials.gov listed 24 tesamorelin records and 33 retatrutide records, and none gives the two together1617. PubMed holds no trial of the pair, and a November 2026 review of weight treatment in people with HIV lists GLP-1 trials there powered to body-composition endpoints among the evidence still missing18.
One mechanism is worth knowing before anyone combines them. Tesamorelin's extra growth hormone can push blood sugar up in some people: average glucose did not change meaningfully in its trials19, but HbA1c reached 6.5% or more in 5% of people on it against 1% on placebo, and its label asks for glucose checks before and during treatment1. Retatrutide pushes the other way: in people with type 2 diabetes, HbA1c fell by up to 1.6 points from 7.7%, against 0.2 on placebo20. How the two pull against each other is untested, so it is a question for the prescriber, with numbers in hand. The stacks page for tesamorelin with ipamorelin (pepvault.app/stacks/tesamorelin-ipamorelin) and the guide to sermorelin, tesamorelin and ipamorelin cover the growth hormone side of combining.
What side effects do people notice on each?
They sit in different places. On tesamorelin they are mostly at the skin and joints: redness or itching where the shot went in, joint aches and some swelling in the legs or feet from fluid, which the label says pass or resolve after stopping1. On retatrutide they are mostly in the gut: nausea, diarrhoea and constipation, rising with the dose and mostly mild to moderate612. The retatrutide side effects guide and the safety guide in this series go through them in full.
Commonly reported: on tesamorelin, a flatter belly and looser waistband while the scale holds; on retatrutide, a much smaller appetite, steady weekly weight loss and queasy days after a step-up.
When to get help Hives, a rash or itching that spreads beyond the injection site, or flushing, can mean an allergic reaction, and tesamorelin's label advises stopping it and getting prompt medical care1.
PepVault logs each side effect with its compound, the day and how strong it was, so you can line it up against the days you stepped up and see when it settles. Log it in PepVault
Where to read more
- Tesamorelin's own trials, the rebound after stopping and the label's monitoring: the guide Tesamorelin and visceral fat, and the compound page (pepvault.app/peptides/tesamorelin).
- Retatrutide's arc and status: Retatrutide week by week, Is retatrutide safe?, When will retatrutide be approved?, and the compound page (pepvault.app/peptides/retatrutide).
- The study pages: pepvault.app/research/retatrutide-sanyal-2024 (the MRI substudy) and pepvault.app/research/tesamorelin-falutz-2007 (the first phase 3 trial).
- Terms: GHRH (pepvault.app/glossary/ghrh), dual and triple agonists (pepvault.app/glossary/dual-and-triple-agonists) and lean mass (pepvault.app/glossary/lean-mass).
Sources
- EGRIFTA WR (tesamorelin) for injection, prescribing information. Theratechnologies. DailyMed, SPL version 2, published Aug 3, 2026. dailymed.nlm.nih.gov
- EGRIFTA SV (tesamorelin) for injection, prescribing information. Theratechnologies. DailyMed, SPL version 9, published Jul 31, 2026. dailymed.nlm.nih.gov
- U.S. Food and Drug Administration. Drugs@FDA: Egrifta (tesamorelin), application 022505, original approval November 10, 2010. accessdata.fda.gov
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. PubMed 18057338
- Makimura H et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012. PubMed 23015655
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023. PubMed 37366315
- ClinicalTrials.gov NCT04881760. A study of LY3437943 in participants who have obesity or are overweight: posted results, change in waist circumference. Eli Lilly and Company. clinicaltrials.gov
- Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024. PubMed 38858523
- Coskun T et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025. PubMed 40609566
- Jastreboff AM et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). N Engl J Med. 2026. PubMed 42814954
- Eli Lilly and Company. Lilly's triple agonist retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1 topline). PR Newswire, May 21, 2026. prnewswire.com
- Bellido V et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. PubMed 42810372
- Eli Lilly and Company. Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial. PR Newswire, Oct 28, 2026. prnewswire.com
- Urva S et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022. PubMed 36354040
- Beach R et al. Differing presentations of excess visceral abdominal fat in people living with HIV: two clinical cases highlighting distinct therapeutic pathways with tesamorelin and glucagon-like peptide-1 receptor agonists. Clin Infect Dis. 2026. PubMed 42139091
- ClinicalTrials.gov. Studies with tesamorelin as an intervention, read November 20, 2026. clinicaltrials.gov
- ClinicalTrials.gov. Studies with retatrutide as an intervention, read November 20, 2026. clinicaltrials.gov
- Manne-Goehler J et al. Weight management in people with HIV. Lancet HIV. 2026. PubMed 43000036
- Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010. PubMed 20554713
- Eli Lilly and Company. Lilly's triple agonist retatrutide successful in two additional Phase 3 obesity trials (TRIUMPH-2 and TRIUMPH-3). PR Newswire, Jul 23, 2026. prnewswire.com
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.